Overview of AML and CML patients' characteristics
| Diagnosis . | FAB subtype . | n . | Female/male, n . | Median age, y . | Median WBC, ×109/L . | BM/PB samples, n . |
|---|---|---|---|---|---|---|
| AML | M0 | 19 | 8/11 | 69 | 2.4 | 26/0 |
| AML | M1 | 56 | 29/27 | 62 | 12.4 | 72/4 |
| AML | M2 | 67 | 29/38 | 62 | 6.7 | 90/4 |
| AML | M3 | 12 | 5/7 | 46 | 5.7 | 16/1 |
| AML | M4/M4eo | 64 | 28/36 | 58 | 34.9 | 87/4 |
| AML | M5a/M5b | 16 | 8/8 | 61 | 30.8 | 22/4 |
| AML | M6 | 9 | 4/5 | 71 | 3.6 | 12/1 |
| AML | n.a. | 31 | 10/21 | 63 | 2.2 | 32/6 |
| AML (all) | n.a. | 274 | 121/153 | 63 | 10.3 | 357/24 |
| CML CP | n.a. | 80 | 38/42 | 56 | 58.5 | 118/53 |
| CML AP | n.a. | 9 | 4/5 | 65 | 178.3 | 7/9 |
| CML BP | n.a. | 8 | 5/3 | 48 | 57.8 | 5/10 |
| CML (all) | n.a. | 97 | 47/50 | 55 | 61.2 | 130/72 |
| Diagnosis . | FAB subtype . | n . | Female/male, n . | Median age, y . | Median WBC, ×109/L . | BM/PB samples, n . |
|---|---|---|---|---|---|---|
| AML | M0 | 19 | 8/11 | 69 | 2.4 | 26/0 |
| AML | M1 | 56 | 29/27 | 62 | 12.4 | 72/4 |
| AML | M2 | 67 | 29/38 | 62 | 6.7 | 90/4 |
| AML | M3 | 12 | 5/7 | 46 | 5.7 | 16/1 |
| AML | M4/M4eo | 64 | 28/36 | 58 | 34.9 | 87/4 |
| AML | M5a/M5b | 16 | 8/8 | 61 | 30.8 | 22/4 |
| AML | M6 | 9 | 4/5 | 71 | 3.6 | 12/1 |
| AML | n.a. | 31 | 10/21 | 63 | 2.2 | 32/6 |
| AML (all) | n.a. | 274 | 121/153 | 63 | 10.3 | 357/24 |
| CML CP | n.a. | 80 | 38/42 | 56 | 58.5 | 118/53 |
| CML AP | n.a. | 9 | 4/5 | 65 | 178.3 | 7/9 |
| CML BP | n.a. | 8 | 5/3 | 48 | 57.8 | 5/10 |
| CML (all) | n.a. | 97 | 47/50 | 55 | 61.2 | 130/72 |
AP, accelerated phase; BP, blast phase; CP, chronic phase; n.a., not available/applicable; PB, peripheral blood; WBC, white blood cell count.